Wedbush Keeps Their Hold Rating on Omeros Corp (OMER)

By Carrie Williams

Wedbush analyst Liana Moussatos reiterated a Hold rating on Omeros Corp (OMERResearch Report) today and set a price target of $18. The company’s shares opened today at $18.56.

According to, Moussatos is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -6.6% and a 36.6% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Allena Pharmaceuticals Inc, and Aquestive Therapeutics Inc.

Omeros Corp has an analyst consensus of Strong Buy, with a price target consensus of $27.75.

See today’s analyst top recommended stocks >>

Based on Omeros Corp’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $24.35 million. In comparison, last year the company had a GAAP net loss of $30.05 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.